Valuation: BICO Group AB

Market Cap 1.14B 118M 103M 95.08M 88.69M 167M 11.13B 170M 443M 5.49B 442M 432M 19.13B P/E 2026 *
-5.52x
P/E 2027 * -10.2x
Enterprise Value 1.08B 112M 97.73M 90.22M 84.15M 159M 10.56B 161M 420M 5.21B 419M 410M 18.15B EV / Sales 2026 *
0.69x
EV / Sales 2027 * 0.64x
Free-Float
68.5%
Yield 2026 *
-
Yield 2027 * -
1 week-2.01%
1 month-14.90%
3 months-3.37%
6 months-24.25%
Current year-24.25%
1 week 1.46
Extreme 1.456
1.51
1 month 1.44
Extreme 1.436
1.75
3 years 1.44
Extreme 1.436
6.4
5 years 1.44
Extreme 1.436
61.2
Manager TitleAgeSince
Chief Executive Officer 54 27/11/2023
Director of Finance/CFO 56 01/03/2026
Chief Operating Officer - 07/01/2026
Director TitleAgeSince
Director/Board Member 73 01/01/2016
Director/Board Member 70 18/12/2019
Director/Board Member 57 17/11/2021
Change 5-day change 1-year change 3-year change Capi.($)
-0.27%-2.01%-54.31%-55.70% 118M
-1.00%+6.82%+23.65%-3.91% 186B
-2.04%-1.36%-26.82%+16.30% 141B
-1.19%+6.43%-3.57%-20.63% 135B
-1.84%-6.40%-60.26%-21.09% 63.44B
-0.79%+4.04%+15.66%-4.10% 52.09B
+0.41%-0.93%-27.33%-34.05% 43.6B
+0.19%+4.86%+12.56%+10.46% 37.52B
+1.67%+4.99%+7.45%+40.71% 36.82B
-1.60%+0.46%-13.58%-21.21% 29.12B
Average -0.79%+2.57%-12.66%-9.32% 80.51B
Weighted average by Cap. -1.09%+3.86%-5.12%-4.12%

Financials

2026 *2027 *
Net sales 1.57B 162M 141M 131M 122M 229M 15.28B 234M 608M 7.54B 607M 593M 26.26B 1.69B 174M 152M 141M 131M 247M 16.47B 252M 656M 8.13B 655M 640M 28.32B
Net income -207M -21.32M -18.66M -17.23M -16.07M -30.28M -2.02B -30.82M -80.23M -995M -80.11M -78.32M -3.47B -112M -11.56M -10.11M -9.34M -8.71M -16.41M -1.09B -16.7M -43.48M -539M -43.42M -42.45M -1.88B
Net Debt -58.35M -6.02M -5.27M -4.86M -4.54M -8.55M -569M -8.7M -22.65M -281M -22.62M -22.11M -979M -64.95M -6.7M -5.87M -5.41M -5.05M -9.52M -634M -9.69M -25.22M -313M -25.18M -24.61M -1.09B
Logo BICO Group AB
BICO Group AB, previously Cellink AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The Company develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.
Employees
-
Date Price Change
01/07/26 1.458 -0.27%
30/06/26 €1.462 -0.95%
29/06/26 €1.476 +1.37%
26/06/26 €1.456 -2.54%
25/06/26 €1.494 -0.27%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
16.16SEK
Average target price
31.00SEK
Spread / Average Target
+91.83%

Quarterly revenue - Rate of surprise